Promising HIV Vaccine Induces Broadly Neutralizing Antibodies in Early Trials

Researchers at Duke University have made significant progress in developing an HIV vaccine that triggers essential immune responses within weeks.

The experimental vaccine targets a stable region on the HIV outer envelope, crucial for neutralizing various strains.
Initial phase 1 trial results show the vaccine elicited strong immune activation in 95% of participants after two doses.
Broadly neutralizing antibodies emerged quickly, a process that typically takes years post-infection.
The trial was halted due to a non-life-threatening allergic reaction, which researchers plan to address in future tests.
Further research aims to enhance the potency and target additional regions of the virus to prevent escape.